Related content

Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34⁺ progenitor-derived dendritic cells

By Fay Joseph   Palucka A.   Paczesny Sophie   Dhodapkar Madhav   Johnston Dennis   Burkeholder Susan   Ueno Hideki   Banchereau Jacques  

Cancer Immunology, Immunotherapy, Vol. 55, Iss. 10, 2006-10 ,pp. : 1209-1218

Springer Publishing Company

Access to resources Recommend Favorite

T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells

By Kyte Jon   Kvalheim Gunnar   Lislerud Kari   thor Straten Per   Dueland Svein   Aamdal Steinar   Gaudernack Gustav  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 5, 2007-05 ,pp. : 659-675

Springer Publishing Company

Access to resources Recommend Favorite

A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells

By Wang Xuelian  

Cancer Immunology, Immunotherapy, Vol. 58, Iss. 2, 2009-02 ,pp. : 301-308

Springer Publishing Company

Access to resources Recommend Favorite

A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells

By Wang Xuelian  

Cancer Immunology, Immunotherapy, Vol. 58, Iss. 2, 2009-02 ,pp. : 309-309

Springer Publishing Company

Access to resources Recommend Favorite

The contribution of dendritic cells to immune responses against urological cancers - T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

By Troy A.   Davidson P.   Atkinson C.   Hart D.  

Urologic Oncology: Seminars and Original Investigations, Vol. 4, Iss. 1, 1998-01 ,pp. : 17-23

Elsevier

Access to resources Recommend Favorite